Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand
Abstract Background: Cannabidiol (CBD) is the non-euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977)…
Abstract Background: Cannabidiol (CBD) is the non-euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977)…
Abstract Background: Approximately 188 million people use cannabis yearly worldwide, and it has recently been legalised in 11 US states,…
Abstract Cannabidiol (CBD) has been used to treat a variety of cancers and inflammatory conditions with controversial results. In previous…
Abstract The design of a composite material structure is often challenging as it is driven by the trade-off between lightweight…
Abstract Cannabis sativa produces hundreds of phytocannabinoids and terpenes. Mycosis fungoides (MF) is the most common type of cutaneous T-cell…
Abstract Background: Cannabis Use Disorder (CUD) is an emerging and diverse challenge among older adults. Methods: The Canadian Coalition for…
Abstract The highly invasive nature of glioblastoma imposes poor prospects for patient survival. Molecular evidence indicates glioblastoma cells undergo an…
Abstract Cellulosic biofuels have not yet reached cost parity with conventional petroleum fuels. One strategy to address this challenge is…
Abstract Background: Substantial advancements were achieved in the management of postoperative pain, however the need for further improvement remains. This…
Abstract Cannabis related online searches are associated with positive attitudes toward medical cannabis, particularly when information is obtained from dispensaries.…